# Prothena Corporation plc Ordinary Shares (PRTA)

> Prothena Corporation plc Ordinary Shares (PRTA) trades at $8.16 (-0.85%) as of 7:45:39 PM EST on Nov 13, 2026, -4.00% over the past month. Market cap is $419.01M, with 15.7 days to cover in short interest.

Canonical: https://massive.com/quote/prta
Data as of: 2026-11-14T00:45:39.510Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$8.16** -0.07 (-0.85%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$8.16** +0.00 (+0.00%)
As of 7:45:39 PM EST on Nov 13, 2026 · After hours

## Stock performance

How Prothena Corporation plc Ordinary Shares (PRTA) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -0.85% |
| 1W | +2.38% |
| 1M | -4.00% |
| YTD | -14.55% |
| 1Y | -20.39% |
| 52-wk range | $7.73 – $11.80 |

From daily closes through Nov 13, 2026.

## Key statistics

Today's trading snapshot for PRTA: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $8.01 – $8.31 |
| Open | $8.21 |
| Prev close | $8.23 |
| Volume | 340.75K |
| Market cap | $419.01M |
| Shares out | 51.35M |

## Valuation and profitability ratios

Valuation and profitability ratios for Prothena Corporation plc Ordinary Shares: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 7.95 |
| P/B | 1.56 |
| P/FCF | — |
| ROE | -8.9% |
| ROA | -8.5% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 13, 2026

## Insider trading

[Prothena Corporation plc Ordinary Shares (PRTA) insider trading](https://massive.com/quote/prta/insider-trading.md): open-market Form 4 buys and sells by Prothena Corporation plc Ordinary Shares insiders over the last 12 months.

## 8-K filings

Material corporate events Prothena Corporation plc Ordinary Shares has disclosed to the SEC on Form 8-K.

- Nov 5, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 5, 2026, Prothena Corporation plc issued a press release announcing its financial results for the third quarter ended September 30, 2026.”
- Oct 29, 2026 · Business update
  “Moponetug and PRX019 are both clinical-stage programs which were part of a research and development collaboration with Bristol Myers Squibb executed in 2018. Bristol Myers Squibb continues to develop moponetug (formerly PRX005), a potential best-in-class antibody for the treatment of Alzheimer's disease ...”
- Oct 2, 2026 · [Executive officer departure](https://massive.com/quote/sec-filings/8-k/executive-departures.md)
  “On October 2, 2026, Chad J. Swanson, Ph.D., Chief Development Officer of Prothena Corporation plc (the "Company") notified the Company that he is resigning from the Company effective October 9, 2026. Dr. Swanson is resigning to accept a position with one of the Company's strategic partners, and, as part of his new role, will assume a leadership role over a program partnered with the Company.”
- May 15, 2026 · Annual meeting results
  “On May 14, 2026, Prothena Corporation plc (the "Company") held its annual general meeting of shareholders, at which the Company's shareholders voted on the following proposals... Proposal No. 1: Election of Directors. The shareholders re-elected the following individuals to the Company's Board of Directors to hold office until no later than the annual general meeting of shareholders in 2029.”
- Feb 27, 2026 · [Share repurchase program](https://massive.com/quote/sec-filings/8-k/share-buybacks.md)
  “On February 27, 2026, the Company announced a share repurchase plan under which the Company may repurchase up to $100.0 million of the Company's outstanding ordinary shares, par value $0.01 per share. The share repurchase plan will expire on December 31, 2026, may be suspended or discontinued at any time, and does not obligate the company to acquire any amount of ordinary shares.”

## PRTA short interest

How heavily PRTA is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 15.7 |
| Short interest | 7.91M |
| Avg volume | 504.2K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## PRTA news

The latest news and headlines about Prothena Corporation plc Ordinary Shares (PRTA).

- [Wall Street Analysts See a 120.16% Upside in Prothena (PRTA): Can the Stock Really Move This High?](https://www.zacks.com/stock/news/3027277/wall-street-analysts-see-a-120-16-upside-in-prothena-prta-can-the-stock-really-move-this-high?cid=CS-ZC-FT-fundamental_analysis|consensus_price_target-3027277) · Zacks Investment Research · Nov 10, 2026 · positive sentiment
- [Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates](https://www.zacks.com/stock/news/3025021/prothena-prta-reports-q3-loss-misses-revenue-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3025021) · Zacks Investment Research · Nov 5, 2026 · negative sentiment
- [Prothena's Partnership Strategy: Growth Driver or Limitation?](https://www.zacks.com/stock/news/3011387/prothena-s-partnership-strategy-growth-driver-or-limitation?cid=CS-ZC-FT-analyst_blog|zer_report_update-3011387) · Zacks Investment Research · Oct 20, 2026 · positive sentiment
- [CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?](https://www.zacks.com/stock/news/3002995/crmd-vs-prta-which-stock-should-value-investors-buy-now?cid=CS-ZC-FT-fundamental_analysis|yseop_template_3-3002995) · Zacks Investment Research · Oct 8, 2026 · positive sentiment
- [Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR \| SNS Insider](https://www.globenewswire.com/news-release/2026/07/07/3323005/0/en/Transthyretin-Amyloidosis-Treatment-Market-Size-to-Reach-USD-35-10-Billion-by-2035-Growing-at-a-14-64-CAGR-SNS-Insider.html) · GlobeNewswire Inc. · Jul 7, 2026 · positive sentiment

## About Prothena Corporation plc Ordinary Shares

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 67 |
| Listed | Dec 18, 2012 |

[Company website](https://www.prothena.com)

## FAQ

### What is the Prothena Corporation plc Ordinary Shares (PRTA) stock price today?

Prothena Corporation plc Ordinary Shares (PRTA) is trading at $8.16 (-0.85% on the day) as of 7:45:39 PM EST on Nov 13, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Prothena Corporation plc Ordinary Shares?

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases.

### What is the short interest in PRTA?

As of Oct 30, 2026, PRTA has 7.91M shares short and 15.7 days to cover.

### What exchange is PRTA listed on?

Prothena Corporation plc Ordinary Shares (PRTA) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time PRTA quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=PRTA`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Prothena Corporation plc Ordinary Shares (PRTA) insider trading](https://massive.com/quote/prta/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
